Incanthera PLC Further re: Director's Dealing (6996U)
2023年3月30日 - 3:00PM
RNSを含む英国規制内ニュース (英語)
TIDMINC
RNS Number : 6996U
Incanthera PLC
30 March 2023
30 March 2023
Incanthera plc
("Incanthera" or the "Company")
Further re: Director's Dealing
The Company advises that, further to its announcement of 13
March 2023, the investment of GBP115,000 by Dr. Simon Ward, a
director of the Company, has been delayed as a result of
administrative reasons by Dr. Ward's pension provider's platform.
As a result of the delay in remitting funds to the Company,
admission of the shares subscribed for by Dr. Ward ("Investment
Shares") to the AQSE Growth market ("Admission") has been postponed
until such time as funds are received. The directors of the Company
and Dr. Ward's pension provider are working to resolve the matter
and it is expected that the investment will be able to be completed
shortly.
Included in the initial application for Admission of the
Investment Shares were 1,079,138 new ordinary shares, issued at the
same price as the Investment Shares of 6.95 pence per share, to
service providers in lieu of contractual amounts owed totalling
approximately GBP75,000 ("Fee Shares"). The Company will proceed
with the Admission of the Fee Shares, which will become effective
at 08:00 a.m. on 30 March 2023
A further announcement will be made in due course on Admission
of the Investment Shares.
Following Admission of the Fee Shares, the Company's enlarged
issued share capital will comprise 77,464,166 ordinary shares of 2
pence each. This figure may be used by shareholders in the Company
as the denominator for the calculations by which they will
determine if they are required to notify their interest in, or a
change in the interest in, the share capital of the Company under
the FCA's Disclosure and Transparency Rules.
This announcement contains inside information for the purposes
of Article 7 of EU Regulation 596/2014 (which forms part of
domestic UK law pursuant to the European Union (Withdrawal) Act
2018).
For further enquiries:
Incanthera plc:
+44 (0) 7831
www.incanthera.com 675747
Tim McCarthy, Chairman tim.mccarthy@incanthera.com +44 (0) 7747
625506
Simon Ward, Chief Executive Officer simon.ward@incanthera.com
+44 (0) 7776
Suzanne Brocks, Head of Communications suzanne.brocks@incanthera.com 234600
Aquis Exchange Corporate Adviser:
Cairn Financial Advisers LLP +44 (0) 20
Jo Turner/Ludo Lazzaretti 7213 0880
Broker:
Stanford Capital Partners Ltd +44 (0) 20
Patrick Claridge/Tom Price/John Howes/Bob Pountney 3650 3650
Notes to Editors
Incanthera is dedicated to innovative technologies in
dermatology and oncology. It seeks to identify and commercialise
inspirational therapeutics combined with uniquely targeted delivery
systems, for innovative solutions to clinical, commercially
relevant unmet needs.
The Company's current lead product and focus is Sol, a
potentially innovative topical product for the treatment of solar
keratosis and the prevention of skin cancers. The Company is
currently focussed upon delivering Sol to a commercial partner.
Originating from the Institute of Cancer Therapeutics ("ICT") at
the University of Bradford, the Company has acquired and developed
a portfolio of specific cancer-targeting therapeutics, with a
strategy to develop each candidate from initial
acquisition/discovery to commercially valuable partnerships at the
earliest opportunity in its development pathway.
For more information on the Company please visit:
www.incanthera.com
@incantheraplc
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
NEXFFFSFVSIAFIV
(END) Dow Jones Newswires
March 30, 2023 02:00 ET (06:00 GMT)
Incanthera (AQSE:INC)
過去 株価チャート
から 5 2024 まで 6 2024
Incanthera (AQSE:INC)
過去 株価チャート
から 6 2023 まで 6 2024